Marizyme Inc

OTCQB:MRZMUnited States

Marizyme, Inc. is a medical technology company. The Company is focused on cardiac and surgical care by delivering innovative solutions for coronary artery bypass graft (CABG) surgery and other surgical procedures. Its product DuraGraft, is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. The Company’s product under development includes MATLOC and MAR-FG-001. MATLOC is a lab-on-chip digital screening and diagnostic device platform being developed for quantitative chronic kidney disease (CKD) assessment. The MAR-FG-001 is a tumescent solution base for fat grafting procedures that is used for plastic and cosmetic surgeries in which fat is transferred from one area of the body to another to correct a defect, replace injured tissue, or to make cosmetic enhancements.

Contact Information

Headquarters

555 HERITAGE DRIVE, SUITE 205JUPITER, FL, United States 33458

Phone

561-935-9955

Fax

770-720-1335

Executives

Director

Vithalbhai Dhaduk

Chief Executive Officer, Secretary, Director

David Barthel

Chief Financial Officer, Treasurer

George Kovalyov

Executive Vice President, Chief Scientific Officer

Catherine Pachuk

Vice President - Finance

Harrison Ross